Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Wilcock, Donna M ^a   Griffin, W Sue T ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE 2; ALPHA1 INTERFERON; ALPHA2 INTERFERON; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 2; COPPER ZINC SUPEROXIDE DISMUTASE; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYSTATHIONINE BETA SYNTHASE; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 2; INTERFERON GAMMA RECEPTOR 2; INTERLEUKIN 1; MEMBRANE PROTEIN; PROTEIN ARGININE METHYLTRANSFERASE 2; PROTEIN S100B; RECEPTOR INTERACTING SERINE THREONINE KINASE 4; T CELL LYMPHOMA INVASION AND METASTASIS 1; UNCLASSIFIED DRUG;

ADAMTS1 GENE; ADAMTS5 GENE; ALZHEIMER DISEASE; AMYLOID PLAQUE; APP GENE; BACE2 GENE; BRAIN DEVELOPMENT; CBS GENE; CELL PROLIFERATION; CHROMOSOME 21; CHROMOSOME REPLICATION; CXADR GENE; DISEASE ASSOCIATION; DOWN SYNDROME; GENE; GENE MAPPING; GENE OVEREXPRESSION; GENE PRODUCT; HUMAN; IFNAR1 GENE; IFNAR2 GENE; IFNGR2 GENE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PRMT2 GENE; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RIPK4 GENE; S100B GENE; SOD1 GENE; TIAM1 GENE;

EID: 84880117155     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-84     Document Type: Review

References (140)

1. Canfield MA, Ramadhani TA, Yuskiv N, Davidoff MJ, Petrini JR, Hobbs CA, Kirby RF, Romitti PA, Collins JS, Devine O, Honein MA, Mai CT, Edmonds LD, Correa A. Improved national prevalence estimates for 18 selected major birth defects-United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2006, 54:1301-1305.
2. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002, 359:1019-1025. 10.1016/S0140-6736(02)08092-3, 11937181.
3. Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, Devine O, Petrini J, Ramadhani TA, Hobbs CA, Kirby RS. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 2006, 76:747-756. 10.1002/bdra.20294, 17051527.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921. 10.1038/35057062, 11237011.
5. van Trotsenburg AS, Heymans HS, Tijssen JG, de Vijlder JJ, Vulsma T. Comorbidity, hospitalization, and medication use and their influence on mental and motor development of young infants with Down syndrome. Pediatrics 2006, 118:1633-1639. 10.1542/peds.2006-1136, 17015556.
6. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998, 150:296-304. 10.1006/exnr.1997.6777, 9527899.
7. Burger PC, Vogel FS. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol 1973, 73:457-476. 1904076, 4271339.
8. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 1995, 52:379-391. 10.1001/archneur.1995.00540280065020, 7710374.
9. Olson MI, Shaw CM. Presenile dementia and Alzheimer's disease in mongolism. Brain 1969, 92:147-156. 10.1093/brain/92.1.147, 4237656.
10. Oliver C, Crayton L, Holland A, Hall S, Bradbury J. A four year prospective study of age-related cognitive change in adults with Down's syndrome. Psychol Med 1998, 28:1365-1377. 10.1017/S0033291798007417, 9854278.
11. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989, 46:849-853. 10.1001/archneur.1989.00520440031017, 2527024.
12. Johannsen P, Christensen JE, Mai J. The prevalence of dementia in Down syndrome. Dementia 1996, 7:221-225.
13. Janicki MP, Dalton AJ. Prevalence of dementia and impact on intellectual disability services. Ment Retard 2000, 38:276-288. 10.1352/0047-6765(2000)038<0276:PODAIO>2.0.CO;2, 10900935.
14. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985, 35:957-961. 10.1212/WNL.35.7.957, 3159974.
15. Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev 2001, 7:172-178. 10.1002/mrdd.1025, 11553933.
16. Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 1988, 331:528-530. 10.1038/331528a0, 2893290.
17. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7611-7615. 10.1073/pnas.86.19.7611, 298116, 2529544.
18. Webb AC, Collins KL, Auron PE, Eddy RL, Nakai H, Byers MG, Haley LL, Henry WM, Shows TB. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res 1986, 5:77-85.
19. D'Eustachio P, Jadidi S, Fuhlbrigge RC, Gray PW, Chaplin DD. Interleukin-1 alpha and beta genes: linkage on chromosome 2 in the mouse. Immunogenetics 1987, 26:339-343. 10.1007/BF00343701, 2889668.
20. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881. 10.1038/42257, 9278049.
21. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989, 86:7606-7610. 10.1073/pnas.86.19.7606, 298115, 2508093.
22. Liu L, Li Y, Van Eldik LJ, Griffin WS, Barger SW. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem 2005, 92:546-553. 10.1111/j.1471-4159.2004.02909.x, 15659225.
23. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996, 17:761-766. 10.1016/0197-4580(96)00104-2, 8892349.
24. Mrak RE. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 2009, 18:473-481.
25. Royston MC, McKenzie JE, Gentleman SM, Sheng JG, Mann DM, Griffin WS, Mrak RE. Overexpression of s100beta in Down's syndrome: correlation with patient age and with beta-amyloid deposition. Neuropathol Appl Neurobiol 1999, 25:387-393. 10.1046/j.1365-2990.1999.00196.x, 10564528.
26. Donnelly RJ, Jacobsen JS, Rasool CG, Blume AJ, Vitek MP. Isolation and expression of multiple forms of beta amyloid protein precursor cDNAs. Prog Clin Biol Res 1989, 317:925-937.
27. Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS. S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998, 71:1421-1428.
28. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, Griffin WS. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000, 20:149-155.
29. Liu L, Aboud O, Jones RA, Mrak RE, Griffin WS, Barger SW. Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. J Neuroinflammation 2011, 8:175. 10.1186/1742-2094-8-175, 3286434, 22171672.
30. Sheng JG, Mrak RE, Griffin WS. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol (Berl) 1997, 94:1-5.
31. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003, 23:1605-1611.
32. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 2002, 72:233-238.
33. Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW. Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett 1994, 176:133-136. 10.1016/0304-3940(94)90066-3, 7830934.
34. Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 1994, 63:1872-1879.
35. Griffin WS, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, Burnett BA, Feoktistova A, Van Eldik LJ. Overexpression of the neurotrophic cytokine S100 beta in human temporal lobe epilepsy. J Neurochem 1995, 65:228-233.
36. Aboud O, Mrak RE, Boop F, Griffin ST. Apolipoprotein epsilon3 alleles are associated with indicators of neuronal resilience. BMC Med 2012, 10:35. 10.1186/1741-7015-10-35, 3352297, 22502727.
37. Sheng JG, Griffin WS, Royston MC, Mrak RE. Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease. Neuropathol Appl Neurobiol 1998, 24:278-283. 10.1046/j.1365-2990.1998.00122.x, 9775393.
38. Sheng JG, Mrak RE, Griffin WS. Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1995, 21:290-301. 10.1111/j.1365-2990.1995.tb01063.x, 7494597.
39. Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol 1994, 53:231-238. 10.1097/00005072-199405000-00003, 8176406.
40. Barger SW, DeWall KM, Liu L, Mrak RE, Griffin WS. Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. J Neuropathol Exp Neurol 2008, 67:773-783. 10.1097/NEN.0b013e318180ec47, 3334532, 18648325.
41. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996, 55:273-279. 10.1097/00005072-199603000-00002, 8786385.
42. Sheng JG, Zhu SG, Jones RA, Griffin WS, Mrak RE. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol 2000, 163:388-391. 10.1006/exnr.2000.7393, 10833312.
43. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, Griffin WS. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001, 39:341-348. 10.1016/S0197-0186(01)00041-9, 11578769.
44. Levin ED, Briggs SJ, Christopher NC, Auman JT. Working memory performance and cholinergic effects in the ventral tegmental area and substantia nigra. Brain Res 1994, 657:165-170. 10.1016/0006-8993(94)90964-4, 7820615.
45. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239. 10.1126/science.7058341, 7058341.
46. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, Kellar KJ. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988, 45:722-724. 10.1001/archneur.1988.00520310028012, 3390025.
47. Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 2003, 24:1023-1027. 10.1016/j.neurobiolaging.2003.09.001, 14643374.
48. Callahan LM, Vaules WA, Coleman PD. Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J Neuropathol Exp Neurol 2002, 61:384-395.
49. Griffin WS, Barger SW. Neuroinflammatory cytokines-the common thread in Alzheimer's pathogenesis. US Neurol 2010, 6(2):19-27. 3297620, 22408651.
50. Pessac B, Godin I, Alliot F. Microglia: origin and development. Bull Acad Natl Med 2001, 185:337-346. discussion 346-337.
51. Perry VH, Gordon S. Macrophages and microglia in the nervous system. Trends Neurosci 1988, 11:273-277. 10.1016/0166-2236(88)90110-5, 2465626.
52. Ling EA. Some aspects of amoeboid microglia in the corpus callosum and neighbouring regions of neonatal rats. J Anat 1976, 121(Pt 1):29-45. 1231817, 1254530.
53. Colton CA, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174-191. 10.2174/187152710791012053, 20205642.
54. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987, 79:195-200. 10.1016/0304-3940(87)90696-3, 3670729.
55. Perlmutter LS, Scott SA, Barron E, Chui HC. MHC class II-positive microglia in human brain: association with Alzheimer lesions. J Neurosci Res 1992, 33:549-558. 10.1002/jnr.490330407, 1484388.
56. Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM. Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers 2006, 22:95-102. 10.1155/2006/276239, 16410654.
57. Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha + microglia and S100beta + astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 1997, 56:285-290. 10.1097/00005072-199703000-00007, 9056542.
58. Anneren G, Edman B. Down syndrome-a gene dosage disease caused by trisomy of genes within a small segment of the long arm of chromosome 21, exemplified by the study of effects from the superoxide-dismutase type 1 (SOD-1) gene. APMIS Suppl 1993, 40:71-79.
59. Rahmani Z, Blouin JL, Creau-Goldberg N, Watkins PC, Mattei JF, Poissonnier M, Prieur M, Chettouh Z, Nicole A, Aurias A, Sinet P-M, Delabar J-M. Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. Proc Natl Acad Sci USA 1989, 86:5958-5962. 10.1073/pnas.86.15.5958, 297750, 2527368.
60. Sinet PM, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M, Noel B, Delabar JM. Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. Biomed Pharmacother 1994, 48:247-252. 10.1016/0753-3322(94)90140-6, 7999986.
61. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884. 10.1126/science.2949367, 2949367.
62. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984, 2:357-369.
63. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135. 10.1016/0006-291X(84)91209-9, 6236805.
64. Margallo-Lana M, Morris CM, Gibson AM, Tan AL, Kay DW, Tyrer SP, Moore BP, Ballard CG. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 2004, 62:1996-1998. 10.1212/01.WNL.0000129275.13169.BE, 15184603.
65. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 1989, 320:1446-1452. 10.1056/NEJM198906013202203, 2566117.
66. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129(Pt 11):2977-2983.
67. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38:24-26. 10.1038/ng1718, 16369530.
68. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185. 10.1126/science.1566067, 1566067.
69. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43:380-383. 10.1002/ana.410430316, 9506555.
70. Lott IT. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 2012, 197:101-121. 3417824, 22541290.
71. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins P, Myers RH, Feldman RG, Pollen D, Drachman D, Growden J, Bruni A, Foncin JF, Salmon D, Frommelt P, Amaducci L, Sorbi S, Piacentini S, Stewart GD, Hobbs WJ, Conneally PM, Gusella JF. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987, 235:885-890. 10.1126/science.2880399, 2880399.
72. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, Taramelli R. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett 2000, 468:59-64. 10.1016/S0014-5793(00)01192-3, 10683441.
73. Zhou S, Zhou H, Walian PJ, Jap BK. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci U S A 2005, 102:7499-7504. 10.1073/pnas.0502768102, 1103709, 15890777.
74. Cheon MS, Dierssen M, Kim SH, Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 2008, 35:339-343. 10.1007/s00726-007-0618-9, 18163181.
75. Anderson JP, Chen Y, Kim KS, Robakis NK. An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. J Neurochem 1992, 59:2328-2331.
76. Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL. Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat Med 1995, 1:829-832. 10.1038/nm0895-829, 7585189.
77. Gandy S, Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie 1994, 76:300-303. 10.1016/0300-9084(94)90162-7, 7819339.
78. Barger SW, Mattson MP. Participation of gene expression in the protection against amyloid beta-peptide toxicity by the beta-amyloid precursor protein. Ann NY Acad Sci 1996, 777:303-309. 10.1111/j.1749-6632.1996.tb34437.x, 8624104.
79. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 2007, 282:11982-11995.
80. Allore RJ, Friend WC, O'Hanlon D, Neilson KM, Baumal R, Dunn RJ, Marks A. Cloning and expression of the human S100 beta gene. J Biol Chem 1990, 265:15537-15543.
81. Haglid KG, Hansson HA, Ronnback L. S-100 in the central nervous system of rat, rabbit and guinea pig during postnatal development. Brain Res 1977, 123:331-345. 10.1016/0006-8993(77)90484-X, 321097.
82. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. Functions of S100 proteins. Curr Mol Med 2013, 13:24-57. 10.2174/156652413804486214, 3707951, 22834835.
83. Kligman D, Marshak DR. Purification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci USA 1985, 82:7136-7139. 10.1073/pnas.82.20.7136, 391325, 3863143.
84. Barger SW, Van Eldik LJ, Mattson MP. S100 beta protects hippocampal neurons from damage induced by glucose deprivation. Brain Res 1995, 677:167-170. 10.1016/0006-8993(95)00160-R, 7606463.
85. Marshak DR. S100 beta as a neurotrophic factor. Prog Brain Res 1990, 86:169-181.
86. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proc Natl Acad Sci USA 1994, 91:5359-5363. 10.1073/pnas.91.12.5359, 43994, 8202493.
87. Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol Aging 1992, 13:1-7. 10.1016/0197-4580(92)90002-F, 1371849.
88. Mrak RE, Griffin WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging 2001, 22:915-922. 10.1016/S0197-4580(01)00293-7, 11754999.
89. Azmitia EC, Griffin WS, Marshak DR, Van Eldik LJ, Whitaker-Azmitia PM. S100 beta and serotonin: a possible astrocytic-neuronal link to neuropathology of Alzheimer's disease. Prog Brain Res 1992, 94:459-473.
90. Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004, 35:2160-2164. 10.1161/01.STR.0000138730.03264.ac, 15297628.
91. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005, 62:1130-1134. 10.1001/archneur.62.7.1130, 16009772.
92. Foerch C, Wunderlich MT, Dvorak F, Humpich M, Kahles T, Goertler M, Alvarez-Sabin J, Wallesch CW, Molina CA, Steinmetz H, Sitzer M, Montaner J. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007, 38:2491-2495. 10.1161/STROKEAHA.106.480111, 17673718.
93. Stein DM, Lindell AL, Murdock KR, Kufera JA, Menaker J, Bochicchio GV, Aarabi B, Scalea TM. Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. J Neurotrauma 2012, 29:1140-1149. 10.1089/neu.2011.2149, 22360297.
94. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 2012, 7:e33606. 10.1371/journal.pone.0033606, 3319096, 22496755.
95. Tavarez MM, Atabaki SM, Teach SJ. Acute evaluation of pediatric patients with minor traumatic brain injury. Curr Opin Pediatr 2012, 24:307-313. 10.1097/MOP.0b013e3283531ce6, 22525719.
96. Strauss GI, Christiansen M, Moller K, Clemmesen JO, Larsen FS, Knudsen GM. S-100b and neuron-specific enolase in patients with fulminant hepatic failure. Liver Transpl 2001, 7:964-970. 10.1053/jlts.2001.28742, 11699032.
97. Kimura T, Budka H. Glial fibrillary acidic protein and S-100 protein in human hepatic encephalopathy: immunocytochemical demonstration of dissociation of two glia-associated proteins. Acta Neuropathol 1986, 70:17-21. 10.1007/BF00689509, 3727931.
98. Mrak RE, Griffin WS. Trisomy 21 and the brain. J Neuropathol Exp Neurol 2004, 63:679-685.
99. Schmechel DE, Goldgaber D, Burkhart DS, Gilbert JR, Gajdusek DC, Roses AD. Cellular localization of messenger RNA encoding amyloid-beta-protein in normal tissue and in Alzheimer disease. Alzheimer Dis Assoc Disord 1988, 2:96-111. 10.1097/00002093-198802020-00002, 3063300.
100. Griffin WS, Ling C, White CL, Morrison-Bogorad M. Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer disease. Alzheimer Dis Assoc Disord 1990, 4:69-78.
101. Yuen S, Smith J, Caruso L, Balan M, Opavsky MA. The coxsackie-adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection. J Mol Cell Cardiol 2011, 50:826-840. 10.1016/j.yjmcc.2011.02.011, 21352828.
102. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997, 272:556-562. 10.1074/jbc.272.1.556, 8995297.
103. Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol 2002, 168:1405-1412.
104. Subasinghe W, Syed I, Kowluru A. Phagocyte-like NADPH oxidase promotes cytokine-induced mitochondrial dysfunction in pancreatic beta-cells: evidence for regulation by Rac1. Am J Physiol Regul Integr Comp Physiol 2011, 300:R12-R20. 10.1152/ajpregu.00421.2010, 3023281, 20943855.
105. Danciger E, Dafni N, Bernstein Y, Laver-Rudich Z, Neer A, Groner Y. Human Cu/Zn superoxide dismutase gene family: molecular structure and characterization of four Cu/Zn superoxide dismutase-related pseudogenes. Proc Natl Acad Sci USA 1986, 83:3619-3623. 10.1073/pnas.83.11.3619, 323574, 3459147.
106. Kim SH, Cohen B, Novick D, Rubinstein M. Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene 1997, 196:279-286. 10.1016/S0378-1119(97)00240-0, 9322767.
107. Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, Ambrogio C, Chiarle R, Marsili G, Battistini A, Giovarelli M, Pellegrini S, Novelli F. Expression of IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma signaling and apoptosis in human T lymphocytes. Immunol Lett 2010, 134:17-25. 10.1016/j.imlet.2010.08.005, 20709103.
108. Rountree RB, Willis CR, Dinh H, Blumberg H, Bailey K, Dean C, Peschon JJ, Holland PM. RIP4 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol 2010, 130:102-112. 10.1038/jid.2009.223, 19626033.
109. Sen U, Givvimani S, Abe OA, Lederer ED, Tyagi SC. Cystathionine beta-synthase and cystathionine gamma-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generation. Am J Physiol Cell Physiol 2011, 300:C155-C163. 10.1152/ajpcell.00143.2010, 3023186, 20943958.
110. Ganesh L, Yoshimoto T, Moorthy NC, Akahata W, Boehm M, Nabel EG, Nabel GJ. Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis. Mol Cell Biol 2006, 26:3864-3874. 10.1128/MCB.26.10.3864-3874.2006, 1488990, 16648481.
111. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997, 94:3352-3356. 10.1073/pnas.94.7.3352, 20373, 9096397.
112. Ito M, Kodama M, Masuko M, Yamaura M, Fuse K, Uesugi Y, Hirono S, Okura Y, Kato K, Hotta Y, Honda T, Kuwano R, Aizawa Y. Expression of coxsackievirus and adenovirus receptor in hearts of rats with experimental autoimmune myocarditis. Circ Res 2000, 86:275-280. 10.1161/01.RES.86.3.275, 10679478.
113. Zen K, Liu Y, McCall IC, Wu T, Lee W, Babbin BA, Nusrat A, Parkos CA. Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils. Mol Biol Cell 2005, 16:2694-2703. 10.1091/mbc.E05-01-0036, 1142417, 15800062.
114. Wei P, Zhao YG, Zhuang L, Hurst DR, Ruben S, Sang QX. Protein engineering and properties of human metalloproteinase and thrombospondin 1. Biochem Biophys Res Commun 2002, 293:478-488. 10.1016/S0006-291X(02)00255-3, 12054626.
115. Miguel RF, Pollak A, Lubec G. Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as down syndrome, Alzheimer's and Pick's disease. Brain Res Mol Brain Res 2005, 133:1-5. 10.1016/j.molbrainres.2004.09.008, 15661359.
116. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 2000, 478:241-245. 10.1016/S0014-5793(00)01854-8, 10930576.
117. Tortorella MD, Liu RQ, Burn T, Newton RC, Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 2002, 21:499-511. 10.1016/S0945-053X(02)00069-0, 12392761.
118. Veluthakal R, Palanivel R, Zhao Y, McDonald P, Gruber S, Kowluru A. Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta cell. Apoptosis 2005, 10:841-850. 10.1007/s10495-005-0431-4, 16133874.
119. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006, 98:453-462. 10.1161/01.RES.0000204727.46710.5e, 16514078.
120. Cheon MS, Kim SH, Yaspo ML, Blasi F, Aoki Y, Melen K, Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part I). Amino Acids 2003, 24:111-117.
121. Lott IT, Head E, Doran E, Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 2006, 3:521-528. 10.2174/156720506779025305, 17168651.
122. Rakhit R, Chakrabartty A. Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim Biophys Acta 2006, 1762:1025-1037. 10.1016/j.bbadis.2006.05.004, 16814528.
123. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz RH, Brown RH. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62. 10.1038/362059a0, 8446170.
124. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Scott RW, Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996, 13:43-47. 10.1038/ng0596-43, 8673102.
125. Usui S, Oveson BC, Iwase T, Lu L, Lee SY, Jo YJ, Wu Z, Choi EY, Samulski RJ, Campochiaro PA. Overexpression of SOD in retina: need for increase in H(2)O(2)-detoxifying enzyme in same cellular compartment. Free Radic Biol Med 2011, 51:1347-1354. 10.1016/j.freeradbiomed.2011.06.010, 3163708, 21736939.
126. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, Lott IT, Schmitt FA, Butterfield DA, Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822, 2012:130-138.
127. Park JI, Strock CJ, Ball DW, Nelkin BD. Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 2005, 29:125-134. 10.1016/j.cyto.2004.10.005, 15613280.
128. Maroun LE. Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. Teratology 1995, 51:329-335. 10.1002/tera.1420510509, 7482354.
129. Maroun LE, Heffernan TN, Hallam DM. Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. J Interf Cytok Res 2000, 20:197-203.
130. Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 2002, 3:1201-1208. 10.1093/embo-reports/kvf236, 1308326, 12446564.
131. Dalal NV, Pranski EL, Tansey MG, Lah JJ, Levey AI, Betarbet RS. RNF11 modulates microglia activation through NF-kappaB signalling cascade. Neurosci Lett 2012, 528:174-179. 10.1016/j.neulet.2012.08.060, 22975135.
132. Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000, 35:151-159. 10.1002/(SICI)1098-2396(200002)35:2<151::AID-SYN8>3.0.CO;2-P, 10611641.
133. Baranano DE, Ferris CD, Snyder SH. Atypical neural messengers. Trends Neurosci 2001, 24:99-106. 10.1016/S0166-2236(00)01716-1, 11164940.
134. Taoka S, Banerjee R. Characterization of NO binding to human cystathionine beta-synthase: possible implications of the effects of CO and NO binding to the human enzyme. J Inorg Biochem 2001, 87:245-251. 10.1016/S0162-0134(01)00335-X, 11744062.
135. Li L, Bhatia M, Moore PK. Hydrogen sulphide-a novel mediator of inflammation?. Curr Opin Pharmacol 2006, 6:125-129. 10.1016/j.coph.2005.10.007, 16487749.
136. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci 2011, 121:459-488. 10.1042/CS20110267, 21843150.
137. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, David M. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001, 104:731-741. 10.1016/S0092-8674(01)00269-0, 11257227.
138. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976, 154:179-184. 1172690, 1275907.
139. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575. 10.1016/0140-6736(92)90865-Z, 1347093.
140. Cua CL, Rogers LK, Chicoine LG, Augustine M, Jin Y, Nash PL, Nelin LD. Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine. Eur J Pediatr 2011, 170:859-863. 10.1007/s00431-010-1361-x, 21120524.